- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Melbourne-made COVID-19 treatment could future-proof Australia
29 September 2021
A COVID-19 treatment using monoclonal antibodies is one step closer thanks to the efforts of Australian researchers.
Scientists found antibodies that blocked the SARS-CoV-2 virus from entering cells in preclinical models.
The discovery paves the way for clinical trials of monoclonal antibody treatments for the prevention of severe COVID-19 infection.
Published in the journal Cell Reports, the research is part of a consortium-led effort, bringing together the expertise of Australian academic and industry leaders in infectious diseases and antibody therapeutics at WEHI, the Doherty Institute, the Burnet Institute, the Kirby Institute, CSL, Affinity Bio and CSIRO.
At a glance
- Researchers have identified monoclonal antibodies that effectively blocked the SARS-CoV-2 virus from entering cells in preclinical models.
- The research indicates these monoclonal antibodies are leading candidates to be developed into a treatment for COVID-19.
- Monoclonal antibody therapies are in current clinical use, both to prevent and treat a range of diseases and could be particularly useful in preventing severe COVID-19 disease in older people and those who are immunocompromised, who are unable to mount a robust immune response from vaccination.
Antibody cocktail blocks SARS-CoV-2 from entering cells
identifying monoclonal antibodies that effectively blocked
the SARS-CoV-2 virus from entering cells
Monoclonal antibodies have emerged as powerful therapeutics for a variety of human diseases, representing seven of the top ten best-selling drugs globally.
Antibodies from recovered COVID-19 patients and CSL’s proprietary antibody library were used to screen for antibodies that were effective against the SARS-CoV-2 virus. The leading two monoclonal antibodies were then combined into an ‘antibody cocktail’.
WEHI Associate Professor Wai-Hong Tham, who co-led the research, said the consortium had screened hundreds of potential antibodies, identifying the top 12 that were the most potent in blocking virus entry.
“By combining the leading antibodies into an antibody cocktail, we were able to test its effectiveness at blocking SARS-CoV-2 from entering cells and reducing viral loads in preclinical models,” she said.
“This antibody cocktail effectively blocked virus entry in these tests and reduced the severity of disease in preclinical models, enabling the infection to be overcome.”
“Our research indicates these monoclonal antibodies are leading candidates to be developed into a treatment for COVID-19.”
Protecting the most vulnerable
Associate Professor Tham said monoclonal antibody treatments could be used to form a ‘protective ring’ around the most vulnerable people during an outbreak or in cases of infection in returned travellers.
“Unlike vaccines, which take several weeks to generate antibodies, antibody-based therapies would provide immediate protection against the virus,” she said.
“In the future, we may be able to use these therapies in people who are immunocompromised or unable to mount a robust immune response to a vaccine. If used early on, these treatments could prevent hospitalisations and serious complications from COVID-19.”
Jobs boost for manufacturing and industry
Doherty Institute laboratory head Professor Stephen Kent, who is an infectious diseases clinician and co-led the research, said the consortium was now working to progress the research to clinical trials in Australia.
“We recently received funding from the Medical Research Future Fund to take this promising research forward into clinical trials for COVID-19,” he said.
“Melbourne’s biomedical precinct has enormous expertise and capability. To be able to deliver a treatment for patients that was researched, designed, manufactured and trialled here in Australia would be an incredible achievement.”
“Our research shows that these monoclonal antibody therapies will be effective against global variants and could future-proof Australia against emerging coronavirus pandemics.”
The development of monoclonal antibody therapies in Australia would also provide a boost to local jobs in manufacturing, academia, biotechnology, and clinical services and strengthen Australia’s reputation as a destination for medical research innovation.
Research assisted by people who have recovered from COVID-19
COVID-19 recovered patient and nursing science student Georgie Johns, who provided blood samples for the study, said she was happy to be able to contribute to the growing body of scientific knowledge of COVID-19 in Australia.
“I contracted COVID-19 early on in the pandemic when not much was known about the virus and I really wanted to do whatever I could to help advance our knowledge about the virus in Australia,” she said.
“It is good to know these treatments might be used to help people working on the frontline in healthcare or to protect the most vulnerable people in our community, for whom vaccines might be less effective.”
This work was made possible with grants from the Medical Research Future Fund and the Victorian Government, and in-kind support from CSL. The research team would like to extend its thanks to the people who contributed samples to the study.
WEHI authors
Phillip Pymm, Melanie Dietrich, Damien Drew, Li-Jin Chan, Katrina Black, Amy Adair, James Cooney, Li Lynn Tan, Matthew O’Neill, Cody Allison, Marc Pellegrini, Alisa Glukhova and Wai-Hong Tham.
Media inquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
WEHI researchers are using extremely small antibodies that occur naturally in alpacas – called nanobodies – to develop biologics that could prevent the COVID-19 coronavirus from binding to human cells – the first step in the virus infection cycle.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak as well as in preparedness for likely future coronaviral disease outbreaks.
WEHI researchers are studying ‘nanobodies’ – tiny immune proteins made by alpacas – in a bid to understand whether they might be effective in blocking SARS-CoV-2, the virus that causes COVID-19.
Medical researchers use antibodies to help answer fundamental biological questions, for example understanding how specific proteins behave, and to assist in developing new therapies.
Find out about antibody-based research at WEHI.
The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19.
We answer some popular questions about the vaccine rollout in Australia.
The Australian Government is providing $5 million to researchers at WEHI to find a new, effective and safe antibody treatment to combat COVID-19.